Global Gene Therapy for Retinal Diseases Market by Indication
Global Gene Therapy for Retinal Diseases Market Based on Region
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapy for Retinal Diseases Market Snapshot
Chapter 4. Global Gene Therapy for Retinal Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Epidemiology: Incidence Prevalence Analysis 2019
4.6.1. Choroideremia (CHM)
4.6.2. Leber congenital amaurosis
4.6.3. Leber’s hereditary optic neuropathy
4.6.4. Retinitis pigmentosa
4.6.5. X-linked retinitis pigmentosa
4.6.6. X-linked retinoschisis
4.6.7. Usher syndrome type 1B
4.6.8. Stargardt disease
4.6.9. Achromatopsia
4.6.10. Neovascular/age-related macular degeneration
4.7. Clinical Trial/Pipeline Analysis
4.8. Industry Analysis – Porter’s Five Forces Analysis
4.9. Technology Advancement in Gene Therapy for Retinal Diseases Market
Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis
5.1. Indication Type & Market Share, 2020 & 2030
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following Indication:
5.2.1. Choroideremia (CHM)
5.2.2. Leber congenital amaurosis
5.2.3. Leber’s hereditary optic neuropathy
5.2.4. Retinitis pigmentosa
5.2.5. X-linked retinitis pigmentosa
5.2.6. X-linked retinoschisis
5.2.7. Usher syndrome type 1B
5.2.8. Stargardt disease
5.2.9. Achromatopsia
5.2.10. Neovascular/age-related macular degeneration
5.2.11. Other Indication
Chapter 6. Gene Therapy for Retinal Diseases Market Segmentation 3: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by Indication, 2020-2030
6.1.2. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by country, 2020-2030
6.1.2.1. U.S.
6.1.2.2. Canada
6.2. Europe
6.2.1. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030
6.2.2. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030
6.2.2.1. Germany
6.2.2.2. Poland
6.2.2.3. France
6.2.2.4. Italy
6.2.2.5. Spain
6.2.2.6. UK
6.2.2.7. Rest of Europe
6.3. Asia Pacific
6.3.1. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030
6.3.2. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030
6.3.2.1. China
6.3.2.2. India
6.3.2.3. Japan
6.3.2.4. Australia
6.3.2.5. Rest of Asia Pacific
6.4. Latin America
6.4.1. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million)
6.4.2. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2030
6.4.2.1. Brazil
6.4.2.2. Rest of Latin America
6.5. MEA
6.5.1. MEA revenue Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million) 2020-2030
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Applied Genetic Technologies Corporation
7.2.2. Adverum Biotechnologies
7.2.3. ProQR Therapeutics
7.2.4. MeiraGTx Limited.
7.2.5. Oxford BioMedica
7.2.6. Horama S.A.
7.2.7. Gensight Biologics
7.2.8. Regenxbio Inc.
7.2.9. Spark Therapeutics, Inc.
7.2.10. Genzyme (Sanofi)
7.2.11. Novartis Pharmaceuticals
7.2.12. Nightstar Therapeutics (Biogen)
7.2.13. Hemera Biosciences
7.2.14. ViGeneron GmbH
7.2.15. Allergan
7.2.16. Eyevensys
7.2.17. Clearside Biomedical
7.2.18. IVERIC bio, Inc.
7.2.19. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.